Eli Lilly Form 4: Alvarez reports deferred stock units, 758 trust shares
Rhea-AI Filing Summary
Ralph Alvarez, a director of Eli Lilly & Co. (LLY), reported a non-derivative acquisition on 08/18/2025. The filing shows an acquisition entry with notation "16.833(1) A $698.05 55,011.413 D" and indicates 758 shares are held indirectly by trust. The reporting person elected to defer the acquired shares as stock units under the Lilly Directors' Deferral Plan; those units will be settled in common stock following his separation from service. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest. The form was signed on 08/19/2025.
Positive
- Transaction disclosed transparently: The Form 4 provides clear details on the deferral election and indirect ownership.
- Deferral into stock units: The reporting person elected to defer compensation into stock units under the Lilly Directors' Deferral Plan, consistent with alignment of director incentives with shareholders.
Negative
- None.
Insights
TL;DR: Routine director compensation deferral reported; disclosure aligns with Section 16 requirements.
The Form 4 documents a director's election to defer compensation into stock units under the Lilly Directors' Deferral Plan, with settlement upon separation from service. This is a common practice for non-employee directors to defer cash fees into equity-like instruments. The filing clearly states an indirect holding of 758 shares via a trust and includes the required disclosure that the reporting person disclaims beneficial ownership except for pecuniary interest. There are no derivative transactions or unusual accelerations disclosed.
TL;DR: Transaction appears immaterial to company valuation; disclosure is procedural.
The entry lists an acquisition on 08/18/2025 recorded as deferred stock units at a price reference of $698.05, with settlement to occur after separation. The details provided are transactional and relate to director compensation mechanics rather than corporate events that would affect cash flow or operations. Ownership amounts reported (including 758 indirect shares) are modest relative to a public company of this size, and the report follows standard Section 16 reporting conventions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 16.833 | $698.05 | $12K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
